In addition, we used suramin as a pharmacological tool to potentially modify VEGF-A expression or concentration, as we have previously shown that suramin in short-term diabetes increases urinary excretion of VEGF-A without altering its blood concentration [20]. Here, VEGFA is linked to diabetes mellitus.